Application of piRNA-AMIPIR in preparation of medicine for improving heart injury after acute myocardial infarction

By screening and identifying piRNA-AMIPIR and its antisense nucleotide Antagomir-AMIPIR, the problems of cardiomyocyte death and cardiac remodeling after acute myocardial infarction were solved, and myocardial injury was improved and function was restored, providing new therapeutic targets and strategies.

CN122440657APending Publication Date: 2026-07-24HARBIN MEDICAL UNIVERSITY
0 Cites 0 Cited by

Patent Information

Application Number
CN202610556633.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-04-24
Publication Date
2026-07-24

AI Technical Summary

Technical Problem

Current technologies lack effective prevention and treatment methods to reverse the massive death of myocardial cells and pathological cardiac remodeling after acute myocardial infarction. Traditional treatments are mostly symptomatic and supportive, and cannot fundamentally improve the process of myocardial damage and cardiac remodeling.

Method used

We screened and identified piRNA-AMIPIR and designed its antisense nucleotide Antagomir-AMIPIR. By inhibiting piRNA-AMIPIR expression, we reduced cardiomyocyte apoptosis, decreased ROS accumulation, inhibited inflammatory cell infiltration, and improved cardiac systolic and diastolic function.

Benefits of technology

It significantly improves cardiac injury after acute myocardial infarction, reduces cardiomyocyte apoptosis, decreases ROS accumulation, reduces inflammatory cell infiltration, improves cardiac contractile function, alleviates myocardial ischemia-related injury, and provides new therapeutic targets and strategies for myocardial infarction.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses an application of piRNA-AMIPIR (piRNA-AMIPIR) in preparation of a medicine for improving heart injury after acute myocardial infarction. According to the invention, high expression of piRNA-AMIPIR in myocardial tissue after acute myocardial infarction (MI) is found for the first time, and the expression level of piRNA-AMIPIR is in positive correlation with myocardial injury degree. After the antisense nucleotide Antagomir-AMIPIR designed on the basis of the piRNA-AMIPIR is administered in a mouse acute myocardial infarction model, inflammatory cell infiltration can be inhibited by reducing myocardial cell apoptosis and reactive oxygen species (ROS) accumulation, the systolic function of the heart can be remarkably improved, and ischemia-induced heart injury can be relieved. According to the application, the potential value of piRNA-AMIPIR serving as a cardiac injury treatment target spot after acute myocardial infarction is defined, the antisense nucleotide of piRNA-AMIPIR provides a new candidate drug and a treatment strategy for clinical treatment of acute myocardial infarction, and important scientific research significance and clinical application prospects are achieved.
Need to check novelty before this filing date? Find Prior Art